12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xalkori crizotinib regulatory update

The European Commission conditionally approved an MAA from Pfizer for Xalkori crizotinib to treat previously treated, advanced non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymphoma kinase ( ALK)-positive. As part...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >